Viridian Therapeutics
VRDN
176 hedge funds and large institutions have $1.23B invested in Viridian Therapeutics in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 67 increasing their positions, 56 reducing their positions, and 27 closing their positions.
96% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $941K
20% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 56
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
1% less funds holding
Funds holding: 178 → 176 (-2)
2.82% less ownership
Funds ownership: 114.94% → 112.12% (-2.8%)
29% less capital invested
Capital invested by funds: $1.75B → $1.23B (-$514M)
33% less funds holding in top 10
Funds holding in top 10: 12 → 8 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$23.4M |
| 2 |
CC
Commodore Capital
New York
|
+$20.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$18.5M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14.6M |
| 5 |
EP
Eversept Partners
New York
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$14.1M |
| 2 |
CCM
Cutter Capital Management
New York
|
-$12.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.3M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$10M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Bessemer Group
Woodbridge,
New Jersey
| – | -$869 | -51 | -60% |
|
|
PA
202
Parallel Advisors
San Francisco,
California
| – | -$192 | -10 | Closed |
|
|
WCM
203
WealthTrak Capital Management
Virginia Beach,
Virginia
| – | -$96 | -5 | Closed |
|
VRDN Hedge Fund Activity: Q1 2025 in Review
176 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2025, worth a combined $1.23B — down 29% from $1.75B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of VRDN and 25 opened new positions — a net loss of 2 holders — while 56 trimmed existing stakes and 67 added.
The largest buyer was Kynam Capital Management, adding an estimated $23.4M. The largest seller was Perceptive Advisors, cutting an estimated $14.1M.
- 176 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2025, down from 178 in Q4 2024.
- Funds reported $1.23B of Viridian Therapeutics stock for Q1 2025, down 29% quarter-over-quarter.
- 25 funds opened new Viridian Therapeutics positions in Q1 2025 and 27 closed out, a net change of -2 holders.
- The largest Viridian Therapeutics buyer in Q1 2025 was Kynam Capital Management, an estimated $23.4M added.
- The largest Viridian Therapeutics seller in Q1 2025 was Perceptive Advisors, an estimated $14.1M sold.
Based on aggregated 13F filings for Q1 2025.